

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## budesonide-glycopyrrolate-formoterol (Breztri Aerosphere)

### Notes:

- Quantity Limits: No
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ Adequate trial is defined as at least 30 days treatment duration

**Initiation (new start) criteria:** Non-formulary **budesonide-glycopyrrolate-formoterol (Breztri Aerosphere)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Pulmonologist
- Patient is at least 18 years of age
- Patient has diagnosis of chronic obstructive pulmonary disease (COPD)
- History of failure, contraindication, or intolerance\* to treatment with an adequate trial<sup>^</sup> of a triple therapy regimen containing an inhaled corticosteroid (ICS), a long acting anti-cholinergic (LAMA), and a long acting beta-agonist (LABA) from separate devices.
- Documented clinical rationale that the patient is unable to separate inhaler products.

*Examples of a triple therapy ICS+LAMA+LABA regimen using multiple inhaler devices (list is not inclusive of all possible triple therapy combinations):*

Inhaler #1	Inhaler #2
Fluticasone propionate/salmeterol (Wixela Inhub, Advair Diskus, Advair HFA)	Tiotropium (Spiriva Respimat, Spiriva HandiHaler)
Budesonide/formoterol (Symbicort)	Tiotropium (Spiriva Respimat, Spiriva HandiHaler)
Tiotropium/olodaterol (Stiolto Respimat)	ciclesonide (Alvesco) fluticasone propionate (Flovent)

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## budesonide-glycopyrrolate-formoterol (Breztri Aerosphere)

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) will be covered on the prescription drug benefit when the following criteria are met:

- Patient is at least 18 years of age
- Patient has diagnosis of chronic obstructive pulmonary disease (COPD)
- History of failure, contraindication, or intolerance\* to treatment with an adequate trial^ of a triple therapy regimen containing an inhaled corticosteroid (ICS), a long acting anti-cholinergic (LAMA), and a long acting beta-agonist (LABA) from separate devices.

*Examples of a triple therapy ICS+LAMA+LABA regimen using multiple inhaler devices (list is not inclusive of all possible triple therapy combinations):*

Inhaler #1	Inhaler #2
Fluticasone propionate/salmeterol (Wixela Inhub, Advair Diskus, Advair HFA)	Tiotropium (Spiriva Respimat, Spiriva HandiHaler)
Budesonide/formoterol (Symbicort)	Tiotropium (Spiriva Respimat, Spiriva HandiHaler)
Tiotropium/olodaterol (Stiolto Respimat)	Ciclesonide (Alvesco) fluticasone propionate (Flovent)